These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25415869)

  • 1. Inhibitors of p21-activated kinases (PAKs).
    Rudolph J; Crawford JJ; Hoeflich KP; Wang W
    J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p21-Activated kinase inhibitors: a patent review.
    Crawford JJ; Hoeflich KP; Rudolph J
    Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p21-activated kinase inhibitors.
    Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
    Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
    Gul M; Fakhar M; Najumuddin ; Rashid S
    PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
    Crawford JJ; Lee W; Aliagas I; Mathieu S; Hoeflich KP; Zhou W; Wang W; Rouge L; Murray L; La H; Liu N; Fan PW; Cheong J; Heise CE; Ramaswamy S; Mintzer R; Liu Y; Chao Q; Rudolph J
    J Med Chem; 2015 Jun; 58(12):5121-36. PubMed ID: 26030457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
    Shao YG; Ning K; Li F
    World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
    Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
    Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P21 activated kinase signaling in cancer.
    Rane CK; Minden A
    Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of p21-activated kinases in cardiovascular development and function.
    Kelly ML; Astsaturov A; Chernoff J
    Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.
    Han D; Wang H; Cui W; Zhang B; Chen BZ
    Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of p21-activated kinases in pancreatic cancer.
    Yeo D; He H; Baldwin GS; Nikfarjam M
    Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors.
    Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M
    J Med Chem; 2018 Jan; 61(1):265-285. PubMed ID: 29190083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
    Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
    Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Potential of Targeting PAK Signaling.
    Senapedis W; Crochiere M; Baloglu E; Landesman Y
    Anticancer Agents Med Chem; 2016; 16(1):75-88. PubMed ID: 26081410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of p-21-activated kinases in cancer progression.
    King H; Nicholas NS; Wells CM
    Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
    Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
    J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
    Park JK; Kim S; Han YJ; Kim SH; Kang NS; Lee H; Park S
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2580-3. PubMed ID: 27117431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UnPAKing the class differences among p21-activated kinases.
    Eswaran J; Soundararajan M; Kumar R; Knapp S
    Trends Biochem Sci; 2008 Aug; 33(8):394-403. PubMed ID: 18639460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR binding and crystal structure reveal that intrinsically-unstructured regulatory domain auto-inhibits PAK4 by a mechanism different from that of PAK1.
    Wang W; Lim L; Baskaran Y; Manser E; Song J
    Biochem Biophys Res Commun; 2013 Aug; 438(1):169-74. PubMed ID: 23876315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.